WO2007015262A3 - A process for the preparation of (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl)]piperidine - Google Patents

A process for the preparation of (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl)]piperidine Download PDF

Info

Publication number
WO2007015262A3
WO2007015262A3 PCT/IN2006/000138 IN2006000138W WO2007015262A3 WO 2007015262 A3 WO2007015262 A3 WO 2007015262A3 IN 2006000138 W IN2006000138 W IN 2006000138W WO 2007015262 A3 WO2007015262 A3 WO 2007015262A3
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
methylenedioxy
fluorophenyl
piperidine
phenoxy
Prior art date
Application number
PCT/IN2006/000138
Other languages
French (fr)
Other versions
WO2007015262A2 (en
Inventor
Ankur Bhupendrakumar Mistry
Mandakini Mutthukumaran Pillai
Vijaykumar Muljibhai Patel
Trinadha Rao Chitturi
Rajamannar Thennati
Original Assignee
Sun Pharmaceutical Ind Ltd
Ankur Bhupendrakumar Mistry
Mandakini Mutthukumaran Pillai
Vijaykumar Muljibhai Patel
Trinadha Rao Chitturi
Rajamannar Thennati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd, Ankur Bhupendrakumar Mistry, Mandakini Mutthukumaran Pillai, Vijaykumar Muljibhai Patel, Trinadha Rao Chitturi, Rajamannar Thennati filed Critical Sun Pharmaceutical Ind Ltd
Publication of WO2007015262A2 publication Critical patent/WO2007015262A2/en
Publication of WO2007015262A3 publication Critical patent/WO2007015262A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Abstract

A process for preparing (-)-trans-4-(4-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine, a compound of formula (I) or pharmaceutically acceptable salts thereof, said process comprising hydrolyzing a compound of formula (II), wherein R may be selected from halo substituted or unsubstituted linear, branched or cyclic alkyl, alkylaryl, arylalkyl, by treatment with a base in a solvent system comprising a polar aprotic water miscible solvent and a hydrocarbon solvent wherein the polar aprotic water miscible solvent is selected from a sulfoxide solvent, an amide solvent or mixture thereof.
PCT/IN2006/000138 2005-04-25 2006-04-24 A process for the preparation of (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl)]piperidine WO2007015262A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN506/MUM/2005 2005-04-25
IN506MU2005 2005-04-25

Publications (2)

Publication Number Publication Date
WO2007015262A2 WO2007015262A2 (en) 2007-02-08
WO2007015262A3 true WO2007015262A3 (en) 2009-05-07

Family

ID=37709012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000138 WO2007015262A2 (en) 2005-04-25 2006-04-24 A process for the preparation of (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl)]piperidine

Country Status (1)

Country Link
WO (1) WO2007015262A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009138999A2 (en) * 2008-05-06 2009-11-19 Matrix Laboratories Ltd. Process for the preparation of paroxetine hydrochloride
CN112521377A (en) * 2020-11-26 2021-03-19 北京福元医药股份有限公司 Continuous preparation method of paroxetine hydrochloride

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0810225A1 (en) * 1996-05-31 1997-12-03 Asahi Glass Company Ltd. Process for producing paroxetine
WO2000078753A1 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Process for the preparation of paroxetine and structurally related compounds
WO2001029032A1 (en) * 1999-10-20 2001-04-26 Smithkline Beecham Plc Process for the preparation of paroxetine
WO2002066466A1 (en) * 2001-02-21 2002-08-29 Synthon B.V. Process to produce paroxetine
US6956121B2 (en) * 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0810225A1 (en) * 1996-05-31 1997-12-03 Asahi Glass Company Ltd. Process for producing paroxetine
WO2000078753A1 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Process for the preparation of paroxetine and structurally related compounds
WO2001029032A1 (en) * 1999-10-20 2001-04-26 Smithkline Beecham Plc Process for the preparation of paroxetine
WO2002066466A1 (en) * 2001-02-21 2002-08-29 Synthon B.V. Process to produce paroxetine
US6956121B2 (en) * 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates

Also Published As

Publication number Publication date
WO2007015262A2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
NO331165B1 (en) Derivatives of dioxane-2-alkylcarbamates, processes for their preparation and use thereof for the preparation of medicaments
AP9901442A0 (en) 4-(2-Keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists.
WO2007081570A3 (en) Cholesteryl ester transfer protein inhibitors
HK1167658A1 (en) Composition for the preparation of 17-vinyl- triflates as intermediates 17--
WO2005037781A3 (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
NO20071577L (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory diseases
DE60317326D1 (en) PHENYL ALKANIC ACID AND PHENYLOXYALKANIC DERIVATIVES AS HPPAR ACTIVATORE
TW200505834A (en) Sulfamide derivative and the pharmaceutical composition thereof
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
EP2269694A3 (en) Antituberculous composition comprising oxazole compounds
MX2011005090A (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidi ne compound.
ATE332304T1 (en) CEFDINIR SALTS AS INTERMEDIATE PRODUCTS
MX2009006334A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives.
ATE528301T1 (en) METHOD FOR PRODUCING SUBSTITUTED SULFOXIDE COMPOSITIONS
WO2004052891A8 (en) Heterocyclic compounds, preparation method thereof and use of same as medicaments, such as anti-bacterial medicaments and beta-lactamase inhibitors
BRPI0411603A (en) 4- (Aminomethyl) piperidine benzamides as antagonists 5ht4
ATE340791T1 (en) PREPARATION AND USE OF 2-SUBSTITUTED 5-OXO-3-PYRAZOLIDINE CARBOXYLATES
WO2007015262A3 (en) A process for the preparation of (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl)]piperidine
EA200870224A1 (en) BENZO [F] IZININDOL-2-ILPHENYL ACID ACETIC DERIVATIVES AS AN AGONISTS EP EP RECEPTORS
TW200736245A (en) Acid addition salts of optically active dihydropyridine derivatives
WO2004062562A3 (en) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
FR2840900B1 (en) NOVEL ARYL [4-HALOGENO-4- [(HETEROARYL-METHYLAMINO) -METHYL] -PIPERIDIN-1-YL] -METHANONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
WO2004099130A3 (en) 1,2-diarylimidazoles useful as inhibitors of cox
HK1077070A1 (en) Oligosaccharide derivative
MA28930B1 (en) INDOLIN-2-ONE PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06809909

Country of ref document: EP

Kind code of ref document: A2